Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 36.50 GBp
Change Today 0.00 / 0.00%
Volume 37.2K
VAL On Other Exchanges
Symbol
Exchange
London
Munich
As of 3:53 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

24 Greville Street

London, EC1N 8SS

United Kingdom

Phone:

Fax:

ValiRx plc, a biopharmaceutical company, develops novel technologies and products in oncology therapeutics and diagnostics in the United Kingdom and rest of Europe. The company operates in two segments, Drug Development and Sale of Self-Test Drug Kits. Its proprietary GeneICE technology enables selective silencing of genes by targeted histone deacetylation that leads to chromatin condensation. The company’s lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials used for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; and VAL401, the reformulation of a generic drug, which is in pre-clinical stage for the treatment of lung cancer and other oncology indications. Its drug candidates also comprise VAL101, a novel therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that is implicated carcinomas. In addition, the company engages in the development of NAV3, a cancer screening test, which is in Phase I clinical trials for the detection of cancer cells in tissue samples. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VAL:LN 36.50 GBp 0.00

VAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VAL.
View Industry Companies
 

Industry Analysis

VAL

Industry Average

Valuation VAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 163.7x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 129.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALIRX PLC, please visit www.valirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.